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Abstract
Aim: To estimate the associations between risk factors and cognitive decline (CD)/
dementia, and the sex differences in these risk factors in individuals with type 2 diabe-
tes, while accounting for the competing risk of death.
Materials and Methods: The Action in Diabetes and Vascular Disease: Preterax and
Diamicron Modified Release Controlled Evaluation (ADVANCE) trial of 11,140 indi-
viduals with type 2 diabetes was used to estimate the odds of CD/dementia using
multinomial logistic regression.
Results: During a median 5-year follow-up, 1827 participants (43.2% women) had
CD/dementia (1718 with CD only; 21 with dementia only; 88 with CD and dementia),
and 929 (31.0% women) died without CD/dementia. Women had lower odds of
CD/dementia than men (odds ratio [OR] [95% confidence interval], 0.88 [0.77, 1.00]);
older age, higher total cholesterol, HbA1c, waist circumference, waist-to-height ratio,
moderately increased albumin-creatinine ratio, stroke/transient ischaemic attack and
retinal disease were each associated with greater odds of CD/dementia; higher years
at education completion, baseline cognitive function, taller stature and current
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alcohol use were inversely associated. Higher waist circumference (women-to-men
ratio of ORs [ROR], 1.05 [1.00, 1.10] per 5 cm) and presence of anxiety/depression
(ROR, 1.28 [1.01, 1.63]) were associated with greater ORs for CD/dementia in
women than men.
Conclusions: Several risk factors were associated with CD/dementia. Higher waist
circumference and mental health symptoms were more strongly associated with
CD/dementia in women than men. Further studies should examine the mechanisms
that underlie these sex differences.
K E YWORD S
cohort study, randomized trial, type 2 diabetes
1 | INTRODUCTION
Diabetes, cognitive dysfunction and dementia each account for a large
portion of the global health burden,1–3 and the growing prevalence of
these conditions can have substantial impacts on the ageing popula-
tion.4,5 Cognitive dysfunction has been increasingly recognized as a
major co-morbidity in people with diabetes.6 People with diabetes
also have an increased risk of dementia,7–11 as well as accelerated
cognitive decline (CD) than those without diabetes.12
Despite these consistent associations, the extent to which
explanatory factors contribute to the excess risk of CD and dementia
in type 2 diabetes remains uncertain,6 and recommendations to guide
clinicians in managing and preventing cognitive dysfunction in people
with diabetes are scarce.3 While risk factor modification is important
in preventing CD and dementia,13 the effect of the risk factors may
be modified by sex, and the manifestations can be different.14,15 A
series of recent publications highlighted the need to better character-
ize the effects of risk factors on CD and dementia by sex.14–17 In gen-
eral populations, women also exhibit greater deterioration of
cognition,18 and the transition from normal cognition to dementia
may be more abrupt compared with men at an older age.19 Diabetes
has also been associated with a greater relative risk of vascular
dementia in women than men.11 The risk of cognitive impairment may
be higher in women than men in diabetes,20 although the literature is
sparse.
Diabetes is also associated with nearly double the risk of prema-
ture death compared with people without diabetes.21 Competing risk
of death has only been accounted in a number of studies,9,10,22,23
despite CD and dementia requiring a follow-up measurement, which
death may preclude. Death as a competing risk should therefore be
examined to avoid biased estimates, particularly in people with diabe-
tes given their heightened risk of CD, dementia and death.
This study sought to provide estimates of relative risks between
common cardiometabolic and lifestyle risk factors and CD/dementia,
while considering death as a competing risk. We used data from a
large, well-characterized, international cohort of people with type
2 diabetes, from a randomized control trial. We also explored the
effect modification of sex on these risk factors for CD/dementia, and
the effects of randomized treatments by sex were additionally
prespecified.
2 | MATERIALS AND METHODS
2.1 | Study design and participants
Data for the present study were taken from the Action in Diabetes
and Vascular Disease: Preterax and Diamicron Modified Release Con-
trolled Evaluation (ADVANCE) trial; the main results have been previ-
ously reported.24 In brief, ADVANCE was a 2-by-2 randomized
factorial trial that investigated the effects of blood pressure-lowering
treatment and intensive glucose control. From 2001 to 2003, a total
of 11,140 participants (aged ≥55 years) were recruited from 215 cen-
tres across 20 countries in Asia, Australia, Europe and North America.
All participants had a diagnosis of type 2 diabetes (from the age of
≥30 years), with a history of major macrovascular or microvascular
disease, or with at least one other cardiovascular risk factor. Partici-
pants were randomized to perindopril/indapamide combination blood
pressure lowering compared with matching placebo; and gliclazide-
based intensive glucose therapy (target HbA1c ≤ 48 mmol/mol
[6.5%]) compared with standard glucose control therapy based on
routine guidelines.24 The median follow-up of the intensive glucose
arm was 5.0 years.24,25 All participants provided written informed
consent, and ethical approvals were obtained in all study centres.
2.2 | Putative risk factors
Several major cardiometabolic and lifestyle risk factors for CD and
dementia were selected, based on previous publications in general
and diabetes populations, tempered by the availability of appropriate
variables in ADVANCE.6,13 At study induction, participants responded
to a series of questionnaires soliciting information on demographic
and lifestyle variables, including age, sex, region of residence (catego-
rized as Europe, Asia, Australia/New Zealand and North America25),
ethnicity, age at highest education attainment, physical activity (self-
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reported participating in mild, moderate or vigorous exercise >15 min
at least once per week26), alcohol intake (current or non-current
drinker, with a current drinker defined as currently drinking alcohol
once a week or more) and cigarette smoking (never or ever smoker,
with an ever smoker further categorized into either a current or former
smoker). Blood pressure (systolic and diastolic blood pressure), serum
total cholesterol and HbA1c were measured using standard protocols.24
Hypertension was defined as currently treated hypertension at study
baseline. Urinary albumin-to-creatinine ratio (ACR) was measured based
on single-spot urine samples taken at a random time of day. ACR was
categorized into normal: <30 μg/mg; moderate: ACR ≥30, ≤300 μg/mg;
and severe: ACR >300 μg/mg. Estimated glomerular filtration rate
(eGFR) was calculated using the Chronic Kidney Disease – Epidemiol-
ogy Collaboration (CKD-EPI) equation27 and categorized as normal:
eGFR <60 mL min−1 (1.73 m)−2; mild to moderate reduction: eGFR
≥60, <90 mL min−1 (1.73 m)−2; and severe reduction: eGFR
≥90 mL min−1 (1.73 m)−2. Weight, height and waist circumference were
measured, and body mass index (BMI) (weight [kg]/{height [m]2}) was
calculated. Waist circumference was included as a continuous variable,
as well as categorical variable, based on cut-offs provided by the World
Health Organization (WHO).28 Symptoms of anxiety or depression
were self-reported at study baseline, based on the anxiety/depression
dimension of the three-level version of the EuroQol 5 Dimensions (EQ-
5D) questionnaire.29 History of macrovascular disease (stroke, transient
ischaemic attack [TIA] or myocardial infarction) and microvascular dis-
ease were recorded at baseline. A history of retinal disease was
recorded as positive if the participant was receiving retinal photocoagu-
lation therapy, or had macular oedema, proliferative retinopathy or
blindness believed to be caused by diabetes.
2.3 | Assessment of cognitive function and
dementia
The primary outcome for the current study is a composite of CD or
dementia. Individuals with a prior or current diagnosis of dementia did
not enter the study. Cognitive function was evaluated using the mini-
mental state examination (MMSE)30 at baseline and was subsequently
administered at 2-year intervals during the follow-up on three occa-
sions. Original translated versions of the MMSE questionnaire were
used; if a language was not available in the original version, a contex-
tually appropriate translation of the MMSE was then arranged.
CD was recorded if there was at least a three-point decrement in
MMSE score at any point during the study.31 At each follow-up, when
an individual scored less than 24 on MMSE, or where the physician or
nurse suspected dementia, the individual was referred to a qualified
specialist with expertise in making dementia diagnoses, based on the
Diagnostic and Statistical Manual of Mental Disorders, fourth edition
(DSM-IV).32 The clinical assessment for dementia included an inter-
view with both the patient and a close friend or a relative, wherever
possible. These clinical evaluation methods were standardized across
all study centres. Both CD and dementia were prespecified secondary
outcomes in ADVANCE.24,25
2.4 | Statistical analyses
Baseline characteristics by sex (women vs. men) were summarized as
mean and standard deviation (SD) for continuous variables, and num-
ber with percentages for categorical variables.
Multinomial regression models were used to estimate the odds
ratios (ORs) with 95% confidence intervals (CIs) for outcomes speci-
fied as: 0, had neither CD nor dementia nor died during the study (ref-
erence category); 1, CD or dementia during the study, regardless of
whether the participant died before the end of follow-up; and 2, death
preceding any CD or dementia during the study, included as a com-
peting risk. The association of each risk factor with CD or dementia
was assessed in basic models adjusted for age, sex, region, age at
completion of highest level of education and the treatments randomly
allocated in the randomized controlled trial. Multiple adjusted models
were fit, additionally adjusting for MMSE score, systolic blood pres-
sure, total cholesterol, HbA1c, ACR, eGFR, diabetes duration, waist
circumference, smoking, alcohol consumption and physical activity.
Models for past medical history (stroke/TIA, myocardial infarction and
retinal disease) remained with only basic adjustments. The effects of
randomized treatments in association with CD/dementia were also
assessed.
To address potential effect modification by sex, we investigated
the association between risk factors and CD/dementia by sex, and
models with interaction terms between each risk factor and sex were
used to obtain the women-to-men ratio of odds ratios (ROR) with
95% CIs.
The benefit of incorporating death as a competing risk to CD or
dementia was assessed by comparing the chosen multinomial models
with logistic regression models, where the outcome was specified as:
0 (had neither CD nor dementia during the study [reference cate-
gory]); or 1 (had CD or dementia during the study). Individuals who
died were included in the reference category (i.e. “0”) for the purpose
of these analyses.
Because the current study focuses on CD and dementia as the
primary outcome of interest, the results on death as the multinomial
outcome are not included.
Complete case analyses were undertaken. All analyses were per-
formed in R Studio version 4.0.3 (R Core Team, 2020). All p-values
reported are two-sided, with the 5% threshold used to determine sta-
tistical significance.
3 | RESULTS
3.1 | Baseline characteristics
Table 1 presents the baseline characteristics of the 11,140 partici-
pants in ADVANCE, stratified by sex; 42.5% of the ADVANCE partici-
pants were women, and the mean age at study baseline was
65.8 years (SD = 6.4).
At study baseline, women had a lower age at completion of
highest level of education by around 2 years on average compared
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with men (17.2 vs. 19.4 years); the prevalence of treated hypertension
was higher in women (72.9%) than men (65.6%); over half of all men
and less than a quarter of women had ever smoked (55.9% vs. 23.1%);
men were four times more probable to be a current drinker than
women (43.7% vs. 12.5%); and while men were twice more probable
to have had a history of myocardial infarction (15.8% vs. 6.9%), a
higher percentage of women reported anxiety/depression symptoms
than men (35.5% vs. 22.6%) (Table 1).
3.2 | Follow-up
The median follow-up of the 11,140 participants was 5.0 years, during
which 1827 participants (43.2% women) had CD and/or dementia
(CD only [n = 1718, 43.0% women]; dementia only [n = 21, 42.9%
women]; CD and dementia [n = 88, 47.7% women]); 929 participants
died (31.0% women) without having CD/dementia; and 8384 were
alive without CD/dementia at the end of the study (43.6% women).
TABLE 1 Characteristics of participants in ADVANCE by sex
Characteristics
Sex
Total (n = 11,140)Women (n = 4733) Men (n = 6407)
Age (years) 65.7 (6.3) 65.9 (6.5) 65.8 (6.4)
Region of residence:
Europe, n (%) 2214 (46.8) 2869 (44.8) 5083 (45.6)
Asia, n (%) 1926 (40.7) 2210 (34.5) 4136 (38.1)
Australia/New Zealand, n (%) 477 (10.1) 1008 (15.7) 1485 (13.3)
North America, n (%) 116 (2.45) 320 (4.99) 436 (3.91)
Age at completion of highest education (years) 17.2 (7.0) 19.4 (7.3) 18.4 (7.3)
MMSE score (points) 28.4 (2.1) 28.6 (1.8) 28.5 (1.9)
Blood pressure:
Systolic blood pressure (mmHg) 145.3 (22.2) 144.8 (21.0) 145.0 (21.5)
Diastolic blood pressure (mmHg) 79.8 (11.0) 81.3 (10.9) 80.6 (10.9)
Treated hypertension, n (%) 3452 (72.9) 4203 (65.6) 7655 (68.7)
Total cholesterol (mmol/l) 5.55 (1.2) 4.93 (1.1) 5.20 (1.2)
HbA1c (mmol/mol) 59.5 (17.9) 58.0 (16.3) 58.6 (17.0)
HbA1c (%) 7.60 (1.6) 7.45 (1.5) 7.51 (1.6)
Albumin-to-creatinine ratio (μg/mg) 51.1 (112.6) 53.5 (116.8) 52.5 (115.0)
eGFR (mL min−1 (1.73 m)−2) 72.7 (18.2) 75.8 (16.9) 74.4 (17.5)
Diabetes duration (years) 7.89 (6.19) 7.97 (6.47) 7.94 (6.35)
Body mass index (kg/m2) 28.8 (5.7) 28.0 (4.7) 28.3 (5.2)
Waist circumference (cm) 95.6 (13.1) 100.7 (12.7) 98.6 (13.1)
Height (cm) 158.3 (6.5) 171.2 (7.2) 165.7 (9.4)
Waist-to-height ratio 0.60 (0.08) 0.59 (0.07) 0.59 (0.08)
Ever smoker, n (%) 1092 (23.1) 3582 (55.9) 4674 (42.0)
Current drinker, n (%) 593 (12.5) 2803 (43.7) 3396 (30.5)
Moderate to vigorous physical activity, n (%) 1901 (40.2) 3212 (50.1) 5113 (45.9)
Anxiety/depression, n (%) 1672 (35.5) 1441 (22.6) 3113 (28.1)
Stroke/transient ischaemic attack, n (%) 584 (12.3) 855 (13.3) 1439 (12.9)
Myocardial infarction, n (%) 325 (6.9) 1009 (15.8) 1334 (12.0)
Retinal disease, n (%) 340 (7.2) 455 (7.1) 795 (7.1)
Cognitive decline/dementia, n (%) 789 (16.7) 1038 (16.2) 1827 (16.4)
Cognitive decline only, n (%) 738 (15.6) 980 (15.3) 1718 (15.4)
Dementia only, n (%) 9 (0.2) 12 (0.2) 21 (0.2)
Cognitive decline and dementia, n (%) 42 (0.9) 46 (0.7) 88 (0.8)
Death, n (%) 288 (6.1) 641 (10.0) 929 (8.3)
Abbreviations: eGFR, estimated glomerular filtration rate; MMSE, mini-mental state examination.
Values are mean (standard deviation) unless stated.
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Of those still being followed up at the end of the study, eight had
missing MMSE values (Table 1).
3.3 | Comparative effects of putative risk factors
on CD/dementia
After adjustment for confounding, women had a 12% lower risk of
CD/dementia (OR, 0.88; 95% CI [0.77, 1.00]) compared with men. The
risk of CD/dementia was lower among people in Australia/New Zealand
in comparison with people in Europe (OR, 0.69; [0.58, 0.82]). Older age,
higher total cholesterol, HbA1c, waist circumference, waist-to-height ratio,
moderately increased ACR, prior stroke/TIA and retinal disease were each
associated with a greater risk of CD/dementia; higher education, baseline
cognitive function, taller stature and current alcohol use were inversely
associated (Figure 1). Results from the basic models (Figure S1) for the
association of each risk factor with CD/dementia were broadly similar to
the multiple adjusted results. Alternative categorizations for comparison by
smoking status, waist circumference and hypertension are also presented
(Tables S1–S3). The estimates for waist circumference were no longer sig-
nificant when categorized based on sex-specific cut-offs.
3.4 | Effect modification by sex
There was some evidence of effect modification by sex of common
cardiovascular risk factors (Figure 2). Higher waist circumference
(women-to-men ROR, 1.05, 95% CI [1.00, 1.10] per 5 cm increment)
and presence of anxiety/depression symptoms (ROR, 1.28 [1.01,
1.63]) were more strongly associated with higher odds of
CD/dementia in women than in men (Table 2).
The longitudinal change in MMSE over the study follow-up
showed no difference by sex (slope for women = −0.04293; slope for
men = −0.03891; difference in slopes = 0.001513 [p- value = .897];
Figure S2).
3.5 | Randomized treatment effects
There was no evidence that intensive glucose control (vs. standard
control) or blood pressure lowering (vs. placebo) conferred a lower risk
of CD/dementia, or evidence for any difference in the risk by sex
(Table 3).
F IGURE 1 Odds ratios for the associations between risk factors and cognitive decline or dementia in ADVANCE, after multiple variable
adjustments. All models are adjusted for sex, age, region, age at completion of highest education and randomized treatments. Models were
additionally adjusted for mini-mental state examination (MMSE) score, systolic blood pressure, total cholesterol, HbA1c, albumin-to-creatinine
ratio (ACR), estimated glomerular filtration rate (eGFR), diabetes duration, waist circumference, smoking, alcohol use, physical activity and mental
health symptoms. Models for stroke/transient ischaemic attack (TIA), myocardial infarction and retinal disease were kept basically adjusted for
sex, age, region, age at completion of highest education and randomized treatments. All analyses accounted for the competing risk of death. ACR
was categorized as normal: ACR < 30 μg/mg; moderate: ACR ≥ 30, ≤300 μg/mg; and severe: ACR > 300 μg/mg. eGFR was categorized as normal:
eGFR < 60 mL min−1 (1.73m)−2; mild to moderate reduction: eGFR ≥ 60, <90 mL min−1 (1.73m)−2; and severe reduction: eGFR ≥ 90 mL min−1
(1.73m)−2. BMI, body mass index
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3.6 | Multinomial regression versus logistic
regression
A comparison of the results from the multinomial regression, which
considers death as a competing risk, with traditional logistic regression
that includes death as no-event, is included in Table S4.
4 | DISCUSSION
In our large, well-characterized cohort of individuals with type 2 diabe-
tes, the risk of CD/dementia was greater in men compared with
women. Older age, higher total cholesterol, HbA1c, waist circumfer-
ence, waist-to-height ratio, moderately increased ACR, prior stroke/
TIA and retinal disease were all associated with a greater risk of
CD/dementia, while higher education, baseline cognitive function,
taller stature and alcohol use were associated with a lower risk of
CD/dementia. There were also risk variations by region. Mental health
symptoms and higher waist circumference were associated with a
greater risk of CD/dementia in women in comparison with in men.
There was no evidence that randomized treatments ameliorated the
overall risk of CD/dementia or by sex.
Increased HbA1c has been linked to diabetes-associated cogni-
tive decrements, CD and dementia6,12,33,34; However, when
treatments for improving glycaemic control were considered in
observational studies, there was an indication that some glucose-
lowering agents, such as metformin,35 were associated with a lower
risk of cognitive impairment and dementia.35–38 Intervention studies,
on the other hand, including our own results from the ADVANCE
trial,25 did not yield evidence for intensive glycaemic control amelio-
rating the risk of CD/dementia.1,33,39 While the causative pathway
between diabetes and dementia needs to be further determined,40 a
multifactorial pathogenesis has been suggested for CD and dementia
in diabetes, involving abnormal insulin signalling, cerebrovascular
injury and accelerated neurodegeneration, among many other puta-
tive biological mechanisms.11,40 Insulin resistance can increase ath-
erosclerosis, which subsequently may contribute to the vascular
pathway, leading to cognitive impairment and dementia.41 Endothe-
lial dysfunction in diabetes may also play a role in precipitating neu-
ronal toxicity, resulting in reduced cerebral blood flow and neuronal
injury.6 Further, insulin can modulate the clearance of beta amyloid,
which is a hallmark in Alzheimer's disease (AD) neuropathology.42
Previous neuropathological studies also suggested that diabetes may
accelerate neurodegeneration via a non-vascular pathway, such that
a lower threshold for amyloid is needed for AD to develop in
diabetes,43,44 and given sex differences could plausibly occur at any
stage in these biological processes, possibly under the influence of
sex hormones.
F IGURE 2 Association between risk factors and cognitive decline or dementia – disaggregated by sex (women and men). Multiple adjusted
odds ratios (ORs) from multivariable model with interactions. All models adjusted for age, region, age at completion of highest education and
randomized treatments. Models with the exceptions of past medical history (stroke/transient ischaemic attack [TIA], myocardial infarction and
retinal disease) additionally adjusted for mini-mental state examination (MMSE) score, systolic blood pressure, total cholesterol, HbA1c, albumin-
to-creatinine ratio (ACR), estimated glomerular filtration rate (eGFR), diabetes duration, waist circumference, smoking, alcohol use, physical
activity and mental health symptoms. Models for stroke/TIA, myocardial infarction and retinal disease were kept basically adjusted for sex, age,
region, age at completion of highest education and randomized treatments. All analyses allowed for interactions with sex and accounted for the
competing risk of death. ACR was categorized as normal: ACR < 30 μg/mg; moderate: ACR ≥ 30, ≤300 μg/mg; and severe: ACR > 300 μg/mg.
eGFR was categorized as normal: eGFR < 60 mL min−1 (1.73 m)−2; mild to moderate reduction: eGFR ≥ 60, <90 mL min−1 (1.73 m)−2; and severe
reduction: eGFR ≥ 90 mL min−1 (1.73 m)−2. BMI, body mass index
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Previous studies have reported high blood pressure to be associ-
ated with CD and dementia in community-based populations.45 How-
ever, our results do not support hypertension being a risk factor for
CD/dementia in diabetes. Another observational study also suggested
that hypertension following a diagnosis of diabetes is unlikely to
account for the elevated dementia risk in diabetes.46 The Systolic
Blood Pressure Intervention Trial – The Memory and Cognition in
Decreased Hypertension (SPRINT MIND) study, although excluding
people with diabetes, showed that intensive blood pressure control
significantly reduced the combined rate of mild cognitive impairment
and dementia.47 A recent meta-analysis, which included the
ADVANCE trial, showed that intensive blood pressure lowering was
associated with a lower risk of cognitive impairment or dementia,48
although the populations included were not exclusively in diabetes.
Intensive blood pressure lowering did not reduce the risk of CD or
dementia in ADVANCE.24,48 Similarly, the Action to Control Cardio-
vascular Risk in Diabetes – The Memory in Diabetes (ACCORD
MIND) study in patients with type 2 diabetes did not show a differ-
ence between intensive versus conventional antihypertensive thera-
pies in CD.49 The specific associations between blood pressure and
blood pressure-lowering treatments with CD/dementia in diabetes
populations need to be further characterized.50
Although women had a lower risk of CD/dementia than men,
mental health symptoms were associated with a greater relative risk
of CD/dementia among women compared with men. In diabetes
populations, depression is nearly twice as common compared with the
general population.51 Anxiety and depressive symptoms have been
linked to an increased risk of CD and dementia52,53; and depressive
symptoms have been reported to increase the risk of progression to
dementia in those with mild cognitive impairment.54 Previous studies
in general populations have reported higher rates of affective disor-
ders in women than in men,55 and the risk of mild cognitive impair-
ment was higher in women with depression than in men.56 One
plausible explanation could be that women are more probable to be
prescribed with pharmacological treatments for depression, poten-
tially presenting the problem of overtreatment.57 The use of antide-
pressants has been linked to a greater risk of dementia,58,59 with a
case-control study reporting that the adverse effect of anticholinergic
antidepressants on dementia risk did not attenuate after controlling
for depression.59 Furthermore, sex difference also exists in the metab-
olism of antidepressants.60
Higher waist circumference was found to be more strongly asso-
ciated with CD/dementia in women compared with men. Central obe-
sity has also been linked to CD in people with diabetes.61 A recent
meta-analysis found no evidence that higher waist circumference con-
ferred a greater risk of all-cause dementia, and no sex difference was
reported62; although the study populations included in this meta-
analysis were not exclusively in diabetes. Obesity has previously been
linked to insulin resistance,63 which may increase the risk of dementia
and CD in diabetes. Whether different body composition and fat dis-
tribution observed in women and men with diabetes,20 partially driven
by the influence of sex hormones on visceral obesity,20 can explain
TABLE 2 Multiple adjusted women-to-men ratios of odds ratios














Education Per year 1.00 (0.98, 1.02)
MMSE Per point 1.01 (0.95, 1.07)
Systolic blood
pressure
Per 10 mmHg 0.99 (0.94, 1.04)
Diastolic blood
pressure
Per 5 mmHg 0.99 (0.94, 1.04)
Total cholesterol Per mmol/l 0.99 (0.90, 1.09)
HbA1c Per percent 1.05 (0.98, 1.13)
ACR Moderate vs. normal 0.89 (0.70, 1.13)
Severe vs. normal 0.71 (0.39, 1.28)






Diabetes duration Per year 0.99 (0.97, 1.01)
BMI Per kg/m2 1.01 (0.98, 1.03)
Waist circumference Per 5 cm 1.05 (1.00, 1.10)
Height Per 5 cm 1.00 (0.98, 1.02)
Waist-to-height
ratio
Per SD 1.11 (0.98, 1.25)
Smoking Ever smoked vs. never 0.90 (0.69, 1.16)
Alcohol Current drinker vs. not
current
1.04 (0.76, 1.43)
Physical activity None/mild vs. moderate/
vigorous
1.08 (0.87, 1.35)
Anxiety/depression With symptoms vs. no
symptoms
1.28 (1.01, 1.63)





History of disease vs.
none
1.10 (0.76, 1.58)
Retinal disease History of disease vs.
none
1.03 (0.70, 1.51)
Abbreviations: ACR, albumin-to-creatinine ratio; eGFR, estimated glomerular
filtration rate; MMSE, mini-mental state examination; TIA, transient ischaemic
attack.
All models adjusted for age, region, age at completion of highest education
and randomized treatments. Models except for past medical history
(stroke/TIA, myocardial infarction and retinal disease) additionally adjusted
for MMSE score, systolic blood pressure, total cholesterol, HbA1c, ACR,
eGFR, diabetes duration, waist circumference, smoking, alcohol use,
physical activity and mental health symptoms; models for stroke/TIA,
myocardial infarction, retinal disease adjusted for sex, age, region, age at
completion of highest education and randomized treatments. All models
allowed for interactions with sex. All analyses accounted for the competing
risk of death.
aROR above 1 indicates higher odds ratio for women, and ROR below 1
indicates the odds ratio is higher for men.
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the sex differences in obesity and CD/dementia, requires further
investigation.
Sex hormones mediate the risk of CD and dementia,14,17 and a
decrease in cerebral glucose metabolism related to menopause also
appears to represent a sex-specific pathophysiological mechanism of
AD.64 Importantly, sex hormones can have a range of impact on car-
diometabolic health, including energy metabolism, body composition,
vascular function and inflammatory responses.20 Endocrine imbal-
ances, such as hyperandrogenism in females and hypogonadism in
males, are related to unfavourable cardiometabolic profiles, which
may have a differential influence on cognition in women and men with
diabetes.
Many of the risk factors identified for CD/dementia are also
common diabetes-related co-morbidities and complications,65,66
which are potentially modifiable. Although the risk of diabetes-
related complications can be reduced with optimal glycaemic
control,66 evidence of diabetes-specific treatments lowering the
risk of cognitive dysfunction in people with diabetes is limited,3
such that whether good glycaemic control prevents or treats cogni-
tive dysfunction in diabetes remains unclear.3 While the directions
of the epidemiological links, and the underlying pathophysiological
mechanisms, need to be further determined, clinicians should be
vigilant to recognize these risk factors for CD and dementia, and
particular attention would be prudent in the case of specific combi-
nations of risk factors.
4.1 | Strengths and limitations
To the best of our knowledge, this is the first study to systematically
examine the effect of risk factors, and the sex differences in the effect
of these risk factors, in association with the risk of CD/dementia,
while incorporating death as a competing risk, in a large, well-charac-
terized, international cohort of patients with type 2 diabetes. The
strength of including the competing risk of death should be
highlighted, as such a consideration directly addresses the elevated
mortality rates in men because of other causes, and improves the esti-
mation for CD/dementia risk by sex.9,16,23 This study was further
strengthened by its prospective design within a randomized controlled
trial, and the results from ADVANCE are also broadly generalizable to
patients with type 2 diabetes in community practice.67
The limitations of the current study were, first, we were unable to
examine the effects of other risk factors for CD/dementia, including
hearing loss, apolipoprotein E4 status, any early life exposures
(e.g. nutrition) or any other unmeasured behavioural risk factors, as
well as information on height loss in older life, and sex hormone levels,
such that residual confounding may be possible. Second, the
ADVANCE trial was not designed to assess CD/dementia as the pri-
mary outcome, and we had limited power to detect interactions (see
Supplementary Material S1). Nevertheless, the effect sizes of the sex
interactions are meaningful, and our analyses concentrate on estima-
tion rather than significance. The median 5-year follow-up may not be
sufficient for allowing CD or dementia to develop, given the long pro-
drome and slow development of these conditions. Third, considering
that the onset of CD and dementia is highly insidious, we were unable
to measure the duration of disease with any accuracy, precluding the
use of any time-to-event analyses. Fourth, multiple testing of interac-
tions can result in false positives, given that, for every 20 tests per-
formed with a threshold of 5%, one significant test would be
expected even if there were no real effects. We also acknowledge
that we were unable to determine causality, and we are not intending
to claim that between-person changes would necessarily reflect
within-person changes. Fifth, lifestyle variables (physical activity,
smoking and alcohol use) were self-reported, hence may be subjective
TABLE 3 Randomized treatment effects (intensive glucose control vs. standard control; blood pressure lowering vs. placebo) and the




model OR (95% CI)
p for interaction –
multiadjusted model
Intensive glucose control versus standard control
Intensive Standard
Women 50.2% 49.8% 0.98 (0.84, 1.15) 0.99 (0.85, 1.16) .91
Men 49.9% 50.1% 0.98 (0.86, 1.13) 1.00 (0.87, 1.16)
Overall 50.0% 50.0% 0.98 (0.89, 1.09) 1.00 (0.90, 1.11)
Blood pressure lowering versus placebo
Active Placebo
Women 50.0% 50.0% 0.92 (0.77, 1.10) 0.93 (0.78, 1.12) .52
Men 50.0% 50.0% 1.01 (0.86, 1.18) 1.01 (0.86, 1.19)
Overall 50.0% 50.0% 0.97 (0.86, 1.09) 0.98 (0.87, 1.10)
Note: Overall basic model adjusted for sex, age, region and age at completion of education.
Overall multiple adjusted models additionally adjusted for Mini-Mental State Examination score, systolic blood pressure, total cholesterol, HbA1c, albumin-
to-creatinine ratio, estimated glomerular filtration rate, diabetes duration, waist circumference, smoking, alcohol use, physical activity and mental health
symptoms. Sex-specific coefficients calculated as the interaction term between sex and randomized treatments.
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to reporting bias. Lastly, the use of MMSE for assessing specific cogni-
tive domains has limitations, such that there is no component sensi-
tive to assess executive function, and there is only one item to screen
for visuospatial deficits in MMSE.68 Nevertheless, MMSE is a valid
and widely accepted screening tool for cognitive impairment, and as
an operational tool to monitor cognitive change over time through
serial administration during drug trials and other interventions.
In conclusion, while there is an urgent need for screening cog-
nitive dysfunction in diabetes in routine practice,4 early detection
and management of modifiable risk factors and other co-
morbidities may slow the progression of CD and prevent or delay
the onset of dementia in people with type 2 diabetes. Our findings
may be useful for identifying high-risk individuals to participate in
future trials. Specific mechanisms for the sex differences need to
be further elucidated.
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